Chithra Sangli
Overview
Explore the profile of Chithra Sangli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakamura Y, Kaneva K, Lo C, Neems D, Freaney J, Boulos H, et al.
Clin Cancer Res
. 2024 Nov;
31(2):328-338.
PMID: 39513962
Purpose: Analysis of ctDNA may enable early identification of patients likely to relapse, presenting an opportunity for early interventions and improved outcomes. Tumor-naïve plasma-only approaches for minimal residual disease (MRD)...
2.
Merola D, Campbell U, Lenis D, Schneeweiss S, Wang S, Madsen A, et al.
JAMA Netw Open
. 2024 Sep;
7(9):e2436535.
PMID: 39348118
Importance: The conditions required for health record data sources to accurately assess treatment effectiveness remain unclear. Emulation of randomized clinical trials (RCTs) with health record data and subsequent calibration of...
3.
Gentzler R, Guittar J, Mitra A, Iams W, Driessen T, Schwind R, et al.
Oncol Ther
. 2024 Jul;
12(3):509-524.
PMID: 39037536
Introduction: A dynamic molecular biomarker that can identify early efficacy of immune checkpoint inhibitor (ICI) therapy remains an unmet clinical need. Here we evaluate if a novel circulating tumor DNA...
4.
Aggarwal C, Ben-Shachar R, Gao Y, Hyun S, Rivers Z, Epstein C, et al.
JAMA Netw Open
. 2023 May;
6(5):e2311181.
PMID: 37129893
Importance: There are few studies assessing the association of tumor mutational burden (TMB) and clinical outcomes in a large cohort of patients with diverse advanced cancers. Objective: To clinically validate...
5.
Reddy V, Pollak S, Lindsay B, McElderry H, Natale A, Kantipudi C, et al.
JACC Clin Electrophysiol
. 2018 May;
2(6):691-699.
PMID: 29759747
Objectives: This study sought to assess the correlation between catheter and tissue contact force (CF) stability and 12-month clinical success for atrial fibrillation (AF) ablation. Background: The SMART-AF (Thermocool Smarttouch...
6.
Velazquez E, Samad Z, Al-Khalidi H, Sangli C, Grayburn P, Massaro J, et al.
Am Heart J
. 2015 Nov;
170(5):1050-1059.e3.
PMID: 26542516
Background: We compared 30-day and 1-year survival among high-risk mitral regurgitation (MR) patients treated with the MitraClip (Abbott Vascular, Abbott Park, IL) with matched non-surgically treated patients from the Duke...
7.
Wang A, Sangli C, Lim S, Ailawadi G, Kar S, Herrmann H, et al.
Circ Cardiovasc Interv
. 2015 Jan;
8(1).
PMID: 25593120
Background: Chronic kidney disease (CKD) is strongly related to outcome in cardiovascular diseases. The relationship between treatment of mitral regurgitation (MR) and renal function is not well described. We sought...
8.
Grayburn P, Foster E, Sangli C, Weissman N, Massaro J, Glower D, et al.
Circulation
. 2013 Sep;
128(15):1667-74.
PMID: 24014834
Background: MitraClip has been shown to reduce mitral regurgitation (MR) severity safely but to a lesser degree than surgery. No data exist on the magnitude of MR reduction necessary to...
9.
Liu M, Jeong J, Ambannavar R, Millward C, Baehner F, Sangli C, et al.
Methods Mol Biol
. 2011 Mar;
724:205-37.
PMID: 21370016
Although RNA is isolated from archival fixed tissues routinely for reverse transcription polymerase chain reaction (RT-PCR) and microarray analyses to identify biomarkers of cancer prognosis and therapeutic response prediction, the...
10.
Clark-Langone K, Sangli C, Krishnakumar J, Watson D
BMC Cancer
. 2010 Dec;
10:691.
PMID: 21176237
Background: The Oncotype DX Colon Cancer Assay is a new diagnostic test for determining the likelihood of recurrence in stage II colon cancer patients after surgical resection using fixed paraffin...